C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H1 2016', provides in depth analysis on C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) targeted pipeline therapeutics. 

The report provides comprehensive information on the C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1)
- The report reviews C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) Overview 6
Therapeutics Development 7
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Products under Development by Stage of Development 7
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Products under Development by Therapy Area 8
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Products under Development by Indication 9
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Products under Development by Companies 12
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Products under Development by Universities/Institutes 14
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Companies Involved in Therapeutics Development 22
Dompe Farmaceutici S.p.A. 22
Syntrix Biosystems, Inc. 23
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Drug Profiles 24
DF-2755A - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
ladarixin - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
PAC-G31P - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
reparixin - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
SX-517 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
SX-576 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
SX-682 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Dormant Projects 34
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Discontinued Products 36
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin-8 Receptor A or IL-8 Receptor Type 1 or CD181 or CXCR1) - Featured News & Press Releases 37
Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells 37
Oct 01, 2014: Dompe commitment in oncology against cancer stem cells 38
Sep 25, 2013: Pharmaceutical company Dompe launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation 38
Jul 10, 2013: Dompe announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true 39
Dec 06, 2012: Dompe Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium 40
Oct 23, 2012: Dompe Announces Enrollment Of First Patient In Phase III Trial On Reparixin 42
Oct 24, 2011: Dompe Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress 43
Oct 13, 2011: Dompe's Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 4

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 21
Pipeline by Dompe Farmaceutici S.p.A., H1 2016 22
Pipeline by Syntrix Biosystems, Inc., H1 2016 23
Dormant Projects, H1 2016 34
Dormant Projects (Contd..1), H1 2016 35
Discontinued Products, H1 2016 36